TAM
MDGL icon

Tiverton Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Tiverton Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-250
Closed -$31K – 713
2019
Q1 		$31K Hold
250
– – ﹤0.01% 642
2018
Q4 		$28K Buy
+250
New +$38.7K ﹤0.01% 476

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Tiverton Asset Management's MDGL Position: Q2 2019 in Review

Tiverton Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2019, closing a stake of 250 shares — an estimated $31K sold.

Tiverton Asset Management first reported a position in MDGL in Q4 2018 and held it in 2 quarters. The position peaked at $31K in Q1 2019. 116 funds tracked by Wall St. Rank hold MDGL as of Q2 2019.

  • Tiverton Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Tiverton Asset Management sold 250 Madrigal Pharmaceuticals shares in Q2 2019, an estimated $31K.
  • Tiverton Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Tiverton Asset Management's Madrigal Pharmaceuticals position peaked at $31K in Q1 2019.
  • 116 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2019.

Based on Tiverton Asset Management's 13F filing for Q2 2019, filed 12 Aug 2019.